MSLE — Satellos Bioscience Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421642 ·
Last close
$6.80
Market Cap
$141.76M
52W High
$13.40
52W Low
$5.50
ADV30
38,411
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,043,000 | -9,768,000 | 75,226,000 | 18,697,000 | 4,563,000 |
| Dec 2025 | 0 | — | -7,647,000 | -7,303,000 | 31,889,000 | 9,804,000 | 4,105,000 |
| Sep 2025 | 0 | — | -5,966,000 | -5,821,000 | 37,503,000 | 19,304,000 | 3,503,000 |
| Jun 2025 | 0 | — | -6,367,000 | -5,608,000 | 41,117,000 | 38,217,000 | 2,770,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,596,000
Investing CF
$-9,417,000
Financing CF
$2,241,000
CapEx
$-3,441
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-81,970,000
Inventory
—
Receivables
$370,000
ST Investments
$17,906,000
EBIT TTM
$-26,459,000
Pretax Income TTM
$-24,701,000
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,459,000 | -24,873,000 | 31,889,000 | 4,105,000 | — | -23,596,000 |
| Dec 2024 | 0 | -20,398,000 | -20,634,000 | 50,747,000 | 3,583,000 | — | -18,252,000 |
| Dec 2023 | 0 | -11,656,113 | -11,977,235 | 33,490,000 | 2,734,000 | — | -8,732,851 |
| Dec 2022 | 0 | -6,209,844 | -8,342,175 | 4,567,492 | 2,085,175 | — | -4,260,978 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.84
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRB | SPRUCE BIOSCIENCES, INC. | $142.60M | $51.81 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $142.95M | $12.51 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $146.55M | $7.91 | — |
| EQ | Equillium, Inc. | $146.69M | $2.32 | — |
| CNTB | Connect Biopharma Holdings Ltd | $135.65M | $2.40 | — |
News headlines (Yahoo Finance, 1h cache)
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate
2026-05-18 13:36 · Yahoo
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
2026-05-15 11:00 · Yahoo
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
2026-04-09 11:00 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
2026-04-06 11:54 · Yahoo
Satellos Bioscience: Q4 Earnings Snapshot
2026-03-27 13:15 · Yahoo
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
2026-03-27 11:00 · Yahoo
Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference
2026-03-10 12:12 · Yahoo
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
2026-03-10 11:00 · Yahoo
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2026-02-24 12:00 · Yahoo
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
2026-02-18 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.